Galapagos regains full rights to GPR84 inhibitor GLPG1205
December 16 2014 - 1:39AM
Galapagos NV (Euronext: GLPG) announced today it has agreed with
Janssen Pharmaceutica NV that Galapagos will regain full and
unencumbered rights to the entire GPR84 program going forward,
which includes the inhibitor GLPG1205 and its backup compound
GLPG2196. No further details were disclosed.
GLPG1205 ('1205), works on GPR84, a novel mechanism of action
developed by Galapagos for Inflammatory Bowel Diseases (IBD).
Earlier this year, Galapagos presented compelling pre-clinical
evidence for GPR84 playing a key role in IBD pathology. The
discovery of a selective antagonist of GPR84 led to GLPG1205, which
shows strong efficacy in relevant pre-clinical models for
IBD. Galapagos disclosed last year that '1205 showed good
safety, target engagement, and favorable drug-like properties in
Phase 1 studies in healthy volunteers. Galapagos plans to
initiate Phase 2 trial patient recruitment before year end
2014.
About GPR84
G-coupled protein receptor 84 (GPR84) is a free fatty acid
protein involved in the regulation of macrophages, monocytes, and
neutrophils in the human immune system. Galapagos identified
GPR84 as playing a key role in inflammation, using its proprietary
target discovery platform. GPR84 is over-expressed in
inflammatory disease patients. Galapagos has confirmed using
in vitro models that GPR84 inhibition prevents neutrophil and
macrophage chemotaxis induced by specific triggers, and in relevant
in vivo models that '1205 prevents IBD disease progression.
Novel medicine '1205 is also the first selective inhibitor of GPR84
to be tested in humans, showing good safety, inhibition of GPR84,
and favorable drug-like properties in Phase 1 studies.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising three Phase 2
studies, two Phase 1 studies, five pre-clinical, and 20 discovery
small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed an agreement for the development and
commercialization of GLPG0634. GLPG0634 is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos has another selective JAK1 inhibitor,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be evaluated
clinically for the treatment of IBD; this program has completed a
Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class
molecule that targets inflammatory disorders and has completed
Phase 1. GLPG1690 is a first-in-class compound that targets
pulmonary diseases and is currently in a Phase 1 study. AbbVie
and Galapagos signed an agreement in cystic fibrosis to develop and
commercialize molecules that address mutations in the CFTR
gene. Potentiator GLPG1837 is expected to start Phase 1 this
month. The first Galapagos corrector GLPG2222 is at the
pre-clinical candidate stage. The Galapagos Group, including
fee-for-service subsidiary Fidelta, has around 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in
The Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV Elizabeth Goodwin, Head of
Corporate Communications & IR Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may
involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to
be materially different from any historic or future results,
financial conditions, performance or achievements expressed or
implied by such forward-looking statements. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation
to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based, unless required by law or regulation.
HUG#1880447
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024